Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab InjectionsUnusual Whales·Aug 9 at 07:48 PM02493+0.95%688062+4.50%
Mabwell passes Brazil ANVISA GMP inspection for denosumab biosimilarsPUBT·Aug 9 at 07:00 PM02493+0.95%688062+4.50%
Mabwell Wins NMPA Nod to Test Novel Autoimmune Antibody 9MW5211 in VitiligoTip Ranks·Jul 15 at 07:08 AM02493+0.95%
Mabwell says China NMPA clears 9MW5211 vitiligo trial applicationPUBT·Jul 15 at 07:03 AM02493+0.95%688062+4.50%
Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancersPUBT·Jun 23 at 07:00 PM688062+4.50%02493+0.95%
Mabwell reshapes senior leadership to bolster pharma growth and governanceTip Ranks·Jun 18 at 09:44 AM02493+0.95%
Mabwell Showcases Promising Nectin-4 ADC Data in Cervical Cancer at ESMO Gynae 2026Tip Ranks·Jun 18 at 09:43 AM688062+4.50%02493+0.95%
Mabwell Proposes New Board Line-Up as Current Directors RetireTip Ranks·May 31 at 07:07 AM02493+0.95%
23:30 ETMabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentationsprnewswire·May 21 at 10:32 PM688062+4.50%02493+0.95%
Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push AcceleratesTip Ranks·May 20 at 10:09 AM688062+4.50%02493+0.95%
20:00 ETWorld's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Applicationprnewswire·May 8 at 07:00 PM02493+0.95%688062+4.50%
Mabwell Wins FDA Green Light for First-in-Human Trial of Novel Autoimmune Antibody 9MW5211Tip Ranks·May 8 at 10:07 AM02493+0.95%688062+4.50%
Mabwell Moves Non-Registered Shareholders to Digital Corporate CommunicationsTip Ranks·May 6 at 09:39 AM688062+4.50%02493+0.95%
Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital StructureTip Ranks·May 6 at 09:39 AM02493+0.95%
